Urothelial cancer: state of art in Ukraine and improvement pathways.

Autor:	Pikul M; Department of Plastic and Reconstructive Oncourology, National Cancer Institute of Ukraine.; Department of Oncology, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine., Gordiichuk P; Department of Oncology, Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine., Stakhovsky E; Department of Plastic and Reconstructive Oncourology, National Cancer Institute of Ukraine.
Jazyk:	angličtina
Zdroj:	Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2024 Aug 06; Vol. 86 (9), pp. 5137-5144. Date of Electronic Publication: 2024 Aug 06 (Print Publication: 2024).
DOI:	10.1097/MS9.0000000000002424
Abstrakt:	Aim: This study aims to assess the effectiveness of urothelial cancer treatment in Ukraine, utilizing population-based data from the National Cancer Registry. The primary goal is to evaluate trends and approaches to therapy, with a focus on overall survival rates in patients with urothelial tumors. Materials and Methods: A retrospective cross-sectional analysis was conducted based on the National Cancer Registry, involving 12 698 patients (2008-2020) with urothelial tumors of the upper urinary tract (UTUC) and bladder cancer (BC) who underwent surgical treatment. Demographic indicators, surgical interventions, complications, and survival rates were analyzed. Results: The average age for all patients was 70 years. The number of patients undergoing radical treatment was 1820 (15%) among BC and 573 (59%) among UTUC. The 30-day readmission rate was low for both, with a slightly higher preference for UTUC (2.3 vs. 4.6%). Whereas grade III or higher Cl-Dindo complications were seen in only 0.2% of cases. Notable findings include low frequency of neoadjuvant (7%) and adjuvant chemotherapy (28%) among patients with invasive urothelial carcinomas. Median eGFR for invasive UTUC before and after surgery was 63.2 and 51.4 ml/min, respectively ( P =0.00054). The directly opposite trend was seen in BC-61.2 and 68.7 ml/min, respectively ( P =0.0026).For BC, the overall survival rates by stages were: I-73%, II-49%, III-18%, and IV-11% (χ 2 =1807.207; P =0.000001). As for UTUC, the 5-year overall survival rates corresponded to the literature data, but there was a pronounced negative trend towards a decrease in this indicator after a 10-year period for all stages (χ 2 =146.298; P =0.000003). Conclusion: The study emphasizes the importance of effective systemic treatments, adherence to treatment guidelines, and the need for multidisciplinary consultations among Ukrainian patients with urothelial cancer. Competing Interests: The authors declare no conflicts of interest and no financial interest in preparing this article.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu